You are here: Industry Insights > Ampion

News List

Ampio’s inhaled drug lowers mortality in Covid-19 trial pharmaceutical-technology
April 28, 2021
Ampio Pharmaceuticals has reported that its AP-014 Phase I clinical trial of inhaled drug Ampion showed a 78% improvement in all-cause mortality in Covid-19 patients with respiratory distress.
Ampio reveals preliminary positive results on inhaled Ampion in Covid-19 respiratory distress pharmaceutical-technology
March 17, 2021
Ampio Pharmaceuticals has revealed preliminary positive results of its AP-014 Phase I clinical trial that involves using of inhaled Ampion in treating respiratory distress in patients due to Covid-19.
Ampio Announces Early Positive Data in Inhaled Ampion Trial for COVID-19 Respiratory Distress americanpharmaceuticalreview
February 02, 2021
Ampio Pharmaceuticals announced early positive data from its ongoing U.S. Phase I controlled, observer-blinded clinical trial of inhaled Ampion versus standard of care for patients with COVID-19 respiratory distress (AP-014).
Ampio Provides Update on Clinical Trials for Ampion™ Treatment of COVID-19 Patients prnewswire
January 05, 2021
Ampio Pharmaceuticals, Inc. announced an update on the launch of a new global clinical trial for intravenous ("IV") treatment of COVID-19 with Ampion and provided updates on its ongoing U.S. trial for inhalation treatment of COVID-19.
Ampion Demonstrates Safety In COVID-19 Patients, Initiates Global Trial for IV Ampion americanpharmaceuticalreview
December 21, 2020
Ampio Pharmaceuticals has completed its Phase I clinical trial and has initiated the first steps for a global Phase II clinical trial for intravenous (IV) Ampion treatment in COVID-19 patients.
Ampion Study Advances to 3rd Group of COVID-19 Patients with Respiratory Distress americanpharmaceuticalreview
December 02, 2020
Ampio Pharmaceuticals announced the third group in the Phase I inhaled Ampion™ clinical study is being treated following clearance by the Safety Monitoring Committee (SMC) who found Ampion to be safe and well-tolerated after reviewing the results from ...
FDA Grants IND, Approves Trial Protocol of Inhaled Ampion for COVID-19 americanpharmaceuticalreview
September 27, 2020
Ampio Pharmaceuticals announces the receipt of an Investigational New Drug (IND) from the U.S. Food and Drug Administration (FDA), allowing the Company to proceed with clinical trials for the use of Ampion as an inhalation therapy for respiratory ...
IND granted to Ampion as COVID-19 treatment after Phase I study europeanpharmaceuticalreview
September 23, 2020
The FDA has given the green light to an IND and further Phase I clinical trial of Ampio Pharmaceuticals’ Ampion as an inhaled COVID-19 therapy.
Ampio Preparing Expanded Access FDA Protocol to Study Ampion for Severe COVID-19 ARDS americanpharmaceuticalreview
March 26, 2020
Ampio Pharmaceuticals is preparing an expanded access FDA protocol to study potential benefit of nebulized treatment with Ampion in SARS-Cov-2 (COVID-19) induced Acute Respiratory Distress Syndrome (ARDS).